Furthermore, a study employing lipoyl-based TRPA1 antagonists demonstrated their ability to decrease the migration of osteosarcoma cells and reduce the expression of pro-inflammatory cytokines [8]. The gene discussed is TRPA1; the disease is osteosarcoma.